Business
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
Michael Yu, chairman and chief executive officer of Innovent Biologics, said the deal with Roche will help the company continue to move forward in the cellular therapy space.
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.
Alphamab Oncology, based in Suzhou, China, inked a collaboration deal with Sanofi (China) Investment Co. to advance clinical trials of Alphamab’s KN026 with Sanofi’s Taxotere (docetaxel) in HER2+ breast cancer.
This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.
Poll after poll shows that many Americans – 30% to 50% – are unwilling to be vaccinated against COVID-19 once a vaccine becomes available. Meanwhile, officials are banking on widespread vaccination to allow society to return to normal, without masks or social distancing.
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.